Management of medullary thyroid cancer

Research output: Contribution to journalArticle

Abstract

Molecular genetics analyses have indicated that approximately 55% of medullary thyroid cancer (MTC) tumors bear activating mutations of the RET gene, including inherited and sporadic cases. Tumoral RET mutations, especially M918T, have a strong negative prognostic impact. RET is the most important target for recent systemic therapy trials of MTC, along with vascular endothelial growth factor receptors. This review discusses promising recent clinical trials data for multikinase inhibitors including motesanib, vandetanib, sunitinib, sorafenib, and cabozantinib/XL184. Across multiple studies reported to date, RET mutations, although prevalent in these subjects, have not proven so far to predict whether patients will respond to multikinase inhibitors. In addition to comparing available data for efficacy and toxicity of these agents, the review focuses on critical questions related to appropriate selection of MTC patients for systemic treatment, and how best to integrate these therapies with established modalities of surgery and radiation therapy.

Original languageEnglish (US)
Pages (from-to)87-98
Number of pages12
JournalMinerva Endocrinologica
Volume36
Issue number1
StatePublished - Mar 2011

Fingerprint

Mutation
Vascular Endothelial Growth Factor Receptor
Molecular Biology
Radiotherapy
Therapeutics
Clinical Trials
Genes
Medullary Thyroid cancer
Neoplasms
sorafenib
sunitinib
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
cabozantinib
imetelstat

Keywords

  • Prognosis
  • Radiotherapy
  • Thyroid cancer, medullary

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Endocrinology

Cite this

Management of medullary thyroid cancer. / Ball, Douglas W.

In: Minerva Endocrinologica, Vol. 36, No. 1, 03.2011, p. 87-98.

Research output: Contribution to journalArticle

@article{bb846089fdd94da1b684eab4a3ffebb9,
title = "Management of medullary thyroid cancer",
abstract = "Molecular genetics analyses have indicated that approximately 55{\%} of medullary thyroid cancer (MTC) tumors bear activating mutations of the RET gene, including inherited and sporadic cases. Tumoral RET mutations, especially M918T, have a strong negative prognostic impact. RET is the most important target for recent systemic therapy trials of MTC, along with vascular endothelial growth factor receptors. This review discusses promising recent clinical trials data for multikinase inhibitors including motesanib, vandetanib, sunitinib, sorafenib, and cabozantinib/XL184. Across multiple studies reported to date, RET mutations, although prevalent in these subjects, have not proven so far to predict whether patients will respond to multikinase inhibitors. In addition to comparing available data for efficacy and toxicity of these agents, the review focuses on critical questions related to appropriate selection of MTC patients for systemic treatment, and how best to integrate these therapies with established modalities of surgery and radiation therapy.",
keywords = "Prognosis, Radiotherapy, Thyroid cancer, medullary",
author = "Ball, {Douglas W}",
year = "2011",
month = "3",
language = "English (US)",
volume = "36",
pages = "87--98",
journal = "Minerva Endocrinologica",
issn = "0391-1977",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Management of medullary thyroid cancer

AU - Ball, Douglas W

PY - 2011/3

Y1 - 2011/3

N2 - Molecular genetics analyses have indicated that approximately 55% of medullary thyroid cancer (MTC) tumors bear activating mutations of the RET gene, including inherited and sporadic cases. Tumoral RET mutations, especially M918T, have a strong negative prognostic impact. RET is the most important target for recent systemic therapy trials of MTC, along with vascular endothelial growth factor receptors. This review discusses promising recent clinical trials data for multikinase inhibitors including motesanib, vandetanib, sunitinib, sorafenib, and cabozantinib/XL184. Across multiple studies reported to date, RET mutations, although prevalent in these subjects, have not proven so far to predict whether patients will respond to multikinase inhibitors. In addition to comparing available data for efficacy and toxicity of these agents, the review focuses on critical questions related to appropriate selection of MTC patients for systemic treatment, and how best to integrate these therapies with established modalities of surgery and radiation therapy.

AB - Molecular genetics analyses have indicated that approximately 55% of medullary thyroid cancer (MTC) tumors bear activating mutations of the RET gene, including inherited and sporadic cases. Tumoral RET mutations, especially M918T, have a strong negative prognostic impact. RET is the most important target for recent systemic therapy trials of MTC, along with vascular endothelial growth factor receptors. This review discusses promising recent clinical trials data for multikinase inhibitors including motesanib, vandetanib, sunitinib, sorafenib, and cabozantinib/XL184. Across multiple studies reported to date, RET mutations, although prevalent in these subjects, have not proven so far to predict whether patients will respond to multikinase inhibitors. In addition to comparing available data for efficacy and toxicity of these agents, the review focuses on critical questions related to appropriate selection of MTC patients for systemic treatment, and how best to integrate these therapies with established modalities of surgery and radiation therapy.

KW - Prognosis

KW - Radiotherapy

KW - Thyroid cancer, medullary

UR - http://www.scopus.com/inward/record.url?scp=79960029995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960029995&partnerID=8YFLogxK

M3 - Article

C2 - 21460789

AN - SCOPUS:79960029995

VL - 36

SP - 87

EP - 98

JO - Minerva Endocrinologica

JF - Minerva Endocrinologica

SN - 0391-1977

IS - 1

ER -